The GPNMB Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human hepatic adenocarcinoma cell line SK-HEP-1. This product features targeted disruption of the GPNMB gene, resulting in a loss-of-function model suitable for investigating the diverse biological roles of the GPNMB transmembrane glycoprotein. The polyclonal format provides a genetically heterogeneous knockout population that mirrors the complexity of gene ablation in polyclonal contexts, offering a versatile tool for functional genomics, signaling pathway analysis, and disease modeling without the constraints of single-clone selection.
The SK-HEP-1 host cell line was originally isolated from the ascitic fluid of a patient with liver adenocarcinoma. These cells are a well-established model for hepatocellular carcinoma (HCC) progression and metastasis, characterized by a mixed epithelial-mesenchymal phenotype that endows them with both adherent and invasive properties. SK-HEP-1 cells are widely employed to study tumor cell migration, invasion, and the molecular mechanisms underlying the metastatic cascade, making them particularly relevant for cancer biology research.
GPNMB (glycoprotein non-metastatic melanoma protein B) is a type I transmembrane protein that undergoes proteolytic cleavage by ADAM10 and ADAM17, releasing a soluble ectodomain. It functions both as a cell surface receptor and a secreted ligand, engaging CD44 and integrin ??v??3 to activate focal adhesion kinase (FAK). This engagement triggers downstream signaling cascades, including ERK1/2 and AKT phosphorylation, as well as ??-catenin stabilization, ultimately promoting cell adhesion, migration, and survival. Additionally, GPNMB participates in lysosomal biogenesis and function, and its expression is transcriptionally regulated by MITF, STAT3, and HIF-1??. Key downstream effectors include MMP9, a matrix metalloproteinase critical for extracellular matrix remodeling, and FAK-mediated cytoskeletal reorganization. Through these interactions, GPNMB integrates signals from the tumor microenvironment to drive invasion and immune evasion.
In the context of SK-HEP-1 cells, which natively exhibit mesenchymal traits and robust migratory capacity, the loss of GPNMB offers a powerful system to dissect its contributions to HCC pathogenesis. GPNMB is frequently overexpressed in hepatocellular carcinoma and correlates with poor prognosis and metastatic spread. This knockout model enables the study of how GPNMB-mediated signaling converges with the epithelial-mesenchymal transition (EMT) program and influences the activity of matrix-degrading enzymes like MMP9. Furthermore, because SK-HEP-1 cells retain susceptibility to lysosomal dysfunction and immune regulatory cues, this tool is well suited for exploring GPNMB’s dual roles in lysosomal physiology and tumor-immune interactions.
Researchers can employ this polyclonal knockout population in a variety of experimental paradigms, including Transwell migration and invasion assays to assess metastatic potential, phospho-ERK/AKT immunoblotting to monitor signaling output, and xenograft tumor models to evaluate in vivo growth and spread. The cells are also amenable to flow cytometric analysis of surface markers, co-immunoprecipitation for protein interaction studies, and lysosomal pH measurements. Applications extend to drug resistance profiling and studies of immune cell modulation. For detailed technical information and cell culture protocols, please contact Ascent Research.
